Fig. 6

Host T-cells programmed in situ via PEGDA–PLL implants show higher infiltration into the implant and into the secondary lymphoid organs. Flow cytometry based quantification of percentage of CD3⁺CD8⁺OVA-TCR⁺ cells (a), CD3⁺CD4⁺ and CD3⁺CD8⁺ (b), CD8:CD4 ratio (c) in the explanted scaffolds for bolus and scaffold mediated LV delivery. Quantification of percentage of CD3⁺CD8⁺OVA-TCR⁺ cells, CD4:CD8 ratio and OVA-TCR⁺CD3⁻ cells in spleen (d–f) and inguinal lymph nodes (g–i). ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, one-way ANOVA with Tukey’s test. PEGDA–PLL polyethylene glycol diacrylate poly-L-lysine, OVA ovalbumin, TCR T-cell receptor, BLV bolus lentiviruses, SLV scaffold loaded lentiviruses